Form 4 for TYRA Tyra Biosciences, Inc.
Accepted 2026-02-13 00:00:00 ET · period of report 2026-02-12 · accession 0001193125-26-051534 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MT | 2026-02-13 | 2026-02-12 | TYRA | Bensen Daniel | Chief Discovery Off | S - Sale | $32.87 | -8,000 | 147.0K | -5% | -$263.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-12 | S | D | 2,128 | $31.50 | 152,853 | D | — | — | (F2) Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $31.02 to $31.75. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. |
| 2 | Common | Common Stock | 2026-02-12 | S | D | 5,872 | $33.37 | 146,981 | D | — | — | (F3) Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $32.98 to $33.85. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. |